Views: 722 Downloads: 89

Rania Khalil Moustafa , Mira Farouk Youssef Yacoub , Hesham Mohamed Mahmoud , Mona Osman Abdelhalim

Abstract

To assess the impact of cannabinoid receptor 2-agonist (JWH-133) vs. dexamethasone in rats in a model of adjuvant-induced rheumatoid arthritis. The study utilized male albino rats weighing between 180 and 200 gm. The obtained data from the present study used dexamethasone orally daily for one 1week (1.5mg/kg), Cannabinoid receptor 2 agonists (JWH133) was administered as the other medication, at a dose of 4mg/kg I.P. injection daily for one week. Normal rats that received saline and DMSO showed insignificant changes in all measured parameters. CFA untreated group3 and group 4 showed significant increases in paw edema, rheumatoid factor and histopathological score, and reduction in cartilage thickness, and trabecular thickness. Treatment with dexamethasone orally or JWH133 I.P. decreased the elevated levels of these parameters and improved the decreased cartilage thickness and trabecular thickness. CFA-induced histopathological alterations were alleviated in rats given dexamethasone or a CB 2 agonist (JWH133), as well as in the combination group. CB 2 agonist (JWH133) was effective as dexamethasone in the treatment of RA. The combination therapy regimen of dexamethasone and JWH133 daily for one week produced more apparent improvement of arthritic paw edema, cartilage thickness, and histopathological score than the usage of each drug alone‎.

Citation Formats: